日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Computational pathology features of immune architecture predict clinically relevant outcomes in small-cell lung cancer (SCLC)

免疫结构的计算病理学特征可预测小细胞肺癌(SCLC)的临床相关结果

Barrera, Cristian; Jain, Prantesh; Corredor, Germán; Dam, Tanmoy; Maurya, Himanshu; Pathak, Tilak; Beshai, Boulos; Perimbeti, Stuthi; Jagirdar, Jaishree; Higgins, Kristin; Dowlati, Afshin; Madabhushi, Anant

Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNEC

简报:一项多中心真实世界分析评估了塔拉单抗治疗既往接受过治疗的小细胞肺癌和LCNEC患者的安全性、有效性和ctDNA动态变化。

Fenton, Graeme; Zhang, Annie L; Zhong, Sharon; Tatsuoka, Curtis; Sittig, Michelle; Simms, Alexandra; Mehra, Ranee; Dowlati, Afshin; Owonikoko, Taofeek K; Scilla, Katherine; Hsu, Melinda; Rosner, Samuel

Brief Report: Real-World Outcomes in Patients Living With Human Immunodeficiency Virus and Lung Cancer Treated With Immune Checkpoint Inhibitors

简报:接受免疫检查点抑制剂治疗的人类免疫缺陷病毒合并肺癌患者的真实世界疗效

Hsu, Melinda L; Liu, Fangzhou; Kyasaram, Ravi K; Zhong, Jeffrey; Dowlati, Afshin

Roles of Restricted Mean Survival Time and Restricted Mean Time Lost in Evaluating Immune Checkpoint Inhibitor Efficacy for Extensive-Stage Small Cell Lung Cancer

限制平均生存时间和限制平均损失时间在评估免疫检查点抑制剂对广泛期小细胞肺癌疗效中的作用

Durer, Seren; Fu, Pingfu; Chen, Zhengyi; Dowlati, Afshin

Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [(18)F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials

一项关于南非醉茄叶提取物 (RH324) 治疗晚期非小细胞肺癌的 I 期试验,包括使用 [(18)F]FDG PET/CT 作为短期代谢生物标志物来评估疗效:一种用于评估早期人体临床试验中辅助疗法的新模型

Heo, Jin Uk; Rao, Santosh; Newton, Herbert B; Dowlati, Afshin; Muzic, Raymond F Jr; Kardan, Arash

Comparative outcomes of surpass streamline and evolve flow diverters in intracranial aneurysms: a comprehensive systematic review and meta-analysis of location, size, and morphology

颅内动脉瘤中超越流线型和进化型血流导向装置的比较结果:位置、大小和形态的综合系统评价和荟萃分析

Rashidi, Farhang; Habibi, Mohammad Amin; Sabahi, Mohammadmahdi; Arshadi, Mohammad Reza; Mirjnani, Mohammad Sina; Javadnia, Parisa; Radnia, Parastoo; Mofatteh, Mohammad; Mashayekhi, Mohammad Sadegh; Dowlati, Ehsan; Siddiq, Farhan; Pervez, Mubashir; Vakharia, Kunal; Bauer, Andrew; Obrzut, Michal

Endovascular-assisted microsurgical clipping of ophthalmic segment aneurysms

眼动脉段动脉瘤的血管内辅助显微外科夹闭术

Dowlati, Ehsan; Oh, Seok Yoon; Golub, Danielle; White, Timothy G; Ballout, Ahmad A; Link, Thomas W; Patsalides, Athos; Katz, Jeffrey M; Dehdashti, Amir R

Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer

基底细胞起源决定了癌症中神经内分泌簇谱系的可塑性

Abbie S Ireland,Daniel A Xie #,Sarah B Hawgood #,Margaret W Barbier,Lisa Y Zuo,Benjamin E Hanna,Scarlett Lucas-Randolph,Darren R Tyson,Benjamin L Witt,Ramaswamy Govindan,Afshin Dowlati,Justin C Moser,Anish Thomas,Sonam Puri,Charles M Rudin,Joseph M Chan,Andrew Elliott,Trudy G Oliver

Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer

基底细胞起源决定了癌症中神经内分泌簇谱系的可塑性

Abbie S Ireland ,Daniel A Xie # ,Sarah B Hawgood # ,Margaret W Barbier ,Lisa Y Zuo ,Benjamin E Hanna ,Scarlett Lucas-Randolph ,Darren R Tyson ,Benjamin L Witt ,Ramaswamy Govindan ,Afshin Dowlati ,Justin C Moser ,Anish Thomas ,Sonam Puri ,Charles M Rudin ,Joseph M Chan ,Andrew Elliott ,Trudy G Oliver

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer

用于治疗铂耐药性卵巢癌的髓系靶向抗体 PY159 和 PY314

Yeku, Oladapo O; Barve, Minal; Tan, Winston W; Wang, Judy; Patnaik, Amita; LoRusso, Patricia; Richardson, Debra L; Naqash, Abdul Rafeh; Lynam, Sarah K; Fu, Siqing; Gordon, Michael; Hubbard, Joleen; Kummar, Shivaani; Kyriakopoulos, Christos; Dowlati, Afshin; Chamberlain, Marc; Winer, Ira